Eiger BioPharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: San Carlos CA United States (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2009
NCT00945880
First Marketed Drug
2020
lonafarnib (Zokinvy)
First NDA Approval
2020
lonafarnib (Zokinvy)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Eiger BioPharmaceuticals | Eiger BioPharmaceuticals, Inc | Eiger BioPharmaceuticals, Inc. | EIGER BIOPHARMS | Eiger Group International, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Familial Primary Pulmonary Hypertension (Phase 2)

Hepatitis (Phase 3)

Hepatitis A (Phase 2)

Hepatitis C (Phase 1)

Hepatitis D (Phase 3)

Hepatitis D, Chronic (Phase 2)

Hypertension (Phase 2)

Hypoglycemia (Phase 2)

Infections (Phase 2)

Lymphedema (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 26
  • # of Trial APIs: 16